Lanisidenib

 

Lanisidenib

Cas 2135537-20-9

MF C28H23ClF3N5O4S MW618.03 g/mol

(3S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-1,1-dioxo-1,2-thiazolidine-3-carboxamide

IUPAC Name: (3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3, 3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo-1λ⁶,2-thiazolidine-3-carboxamide

3-Isothiazolidinecarboxamide, N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-, 1,1-dioxide, (3S)-

(3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo1λ6,2-thiazolidine-3-carboxamide
isocitrate dehydrogenase inhibitor, antineoplastic, G5J396CG5J

Lanisidenib is a potent, selective isocitrate dehydrogenase (IDH) inhibitor that exhibits antineoplastic (anti-cancer) activity. It works by targeting abnormal IDH enzymes, which are frequently mutated in various malignancies, such as certain myeloid leukemias and solid tumours. By blocking these mutant enzymes, it halts the production of oncometabolites that drive cancer progression

Research and Availability

The compound is primarily utilized in biochemical research and preclinical drug screening platforms. Specialty chemical suppliers, such as MedChemExpress and AdooQ BioScience, distribute it exclusively for laboratory research

SYN

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2018-05-31

PMID: 29847930

DOI: 10.1021/acs.jmedchem.8b00159

PAT

https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=8FF935A29A689E69F88CA3A23E3DDAED.wapp2nA?docId=US306234699&_cid=P20-MQBQF9-01167-1

Step F: (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-2-(4-cyanopyridin-2-yl-N-(3-fluorophenyl)-isothiazolidine-3-carboxamide 1,1-dioxide

At room temperature, 3-amino-5-Fluorouridine (57 mg, 0.508 mmol) and o-chlorobenzaldehyde (72 mg, 0.512 mmol) were dissolved in methanol, and stirred for 30 min. (S)-2-(4-cyanopyridin-2-yl)isothiazolidine-3-carboxylic acid 1,1-dioxide (136 mg, 0.508 mmol) was then added into the mixed solution, stirred for 10 min, then added with 1,1-difluoro-3-isocyanocyclobutane (prepared according to the method described in patent CN103097340, 60 mg, 0.508 mmol), and stirred overnight. The solvent was removed and the residue was separated by thin layer chromatography, to give the title compound (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-2-(4-cyanopyridin-2-yl-N-(3-fluorophenyl)-isothiazolidine-3-carboxamide 1,1-dioxide (the compound of formula I).

1H-NMR (400 MHz, CDCl 3): δ=8.46 (m, 1H), 7.67 (d, J=8.8 Hz, 1H), 7.63 (s, 1H), 7.22-6.84 (m, 8H), 6.47 (d, J=3.6, 1H), 6.08 (s, 1H), 4.82 (d, J=6.1 Hz, 1H), 4.33 (m, 1H), 3.68-3.60 (m, 1H), 3.40-3.28 (m, 1H), 3.10-2.98 (m, 2H), 2.68-2.38 (m, 4H).

m/z=618 [M+H] +.

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019057142&_cid=P20-MQBQHW-03190-1

A sulfonamide compound with the structure shown in Formula I has the chemical name: (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-isothiazolidin-3-carboxamide 1,1-dioxide.

Step F: (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-isothiazolidin-3-carboxamide 1,1-dioxide

At room temperature, 3-amino-5-fluoropyridine (57 mg, 0.508 mmol) and o-chlorobenzaldehyde (72 mg, 0.512 mmol) were dissolved in methanol and stirred for 30 minutes. Then, (S)-2-(4-cyanopyridin-2-yl)isothiazolidin-3-carboxylic acid 1,1-dioxide (136 mg, 0.508 mmol) was added to the mixture and stirred for 10 minutes. Finally, 1,1-difluoro-3-isocyanocyclobutane (refer to the patent) was added. Prepared by the method described in CN103097340, 60 mg (0.508 mmol), stirred overnight, solvent removed, and separated by thin-layer chromatography to obtain the title compound (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-isothiazolidin-3-carboxamide 1,1-dioxide (compound of formula I). 

[0134]

¹H-NMR(400MHz,CDCl ₃):δ＝8.46(m,1H),7.67(d,J＝8.8Hz,1H),7.63(s,1H),7.22-6.84(m,8H),6.47(d,J＝3.6,1H),6.08(s,1H),4.82(d,J＝6.1Hz,1H),4.33(m,1H),3.68-3.60(m,1H),3.40-3.28(m,1H),3.10-2.98(m,2H),2.68-2.38(m,4H)。

[0135]

m/z＝618[M+H] ⁺。

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

PAT

• Sultam compound and application method thereofPublication Number: US-11111240-B2Priority Date: 2016-03-22Grant Date: 2021-09-07
• Sultam Compound And Application Method ThereofPublication Number: US-2021047314-A1Priority Date: 2016-03-22
• Lactam compounds and methods of using the samePublication Number: CN-113666922-APriority Date: 2016-03-22
• Endosulfonamide compound and method of use thereofPublication Number: TW-201736354-APriority Date: 2016-03-22
• Sultam compound and application method thereofPublication Number: EP-3434671-B1Priority Date: 2016-03-22Grant Date: 2020-10-21
• Internal sulfonamide compounds and methods of use thereofPublication Number: CN-109071471-BPriority Date: 2016-03-22Grant Date: 2021-05-07
• Sultam compounds and methods of use thereofPublication Number: KR-102389985-B1Priority Date: 2016-03-22Grant Date: 2022-04-22
• Endosulfonamide compounds and methods of usePublication Number: TW-I729094-BPriority Date: 2016-03-22Grant Date: 2021-06-01
• Crystalline sulfamide compoundsPublication Number: KR-102707847-B1Priority Date: 2017-09-22Grant Date: 2024-09-23
• Crystalline sulfamide compoundPublication Number: KR-20200057049-APriority Date: 2017-09-22
• Crystalline sulfamide compoundPublication Number: CA-3076405-A1Priority Date: 2017-09-22
• Crystalline sulfamide compoundPublication Number: US-2020291012-A1Priority Date: 2017-09-22
• Crystalline sulfamide compoundPublication Number: US-11254665-B2Priority Date: 2017-09-22Grant Date: 2022-02-22
• Preparation method of lactam compoundPublication Number: CN-118580235-APriority Date: 2023-03-03
• A kind of internal sulfonamide compound crystalPublication Number: CN-111065630-APriority Date: 2017-09-22
• Crystalline sulfamide compoundPublication Number: EP-3686191-A1Priority Date: 2017-09-22
• A kind of internal sulfonamide compound crystallizationPublication Number: CN-111065630-BPriority Date: 2017-09-22Grant Date: 2022-12-30
• Crystalline sulfamide compoundPublication Number: EP-3686191-B1Priority Date: 2017-09-22Grant Date: 2022-12-14

///////////lanisidenib, anax labs, isocitrate dehydrogenase inhibitor, antineoplastic, G5J396CG5J

#lanisidenib, #anax labs, #isocitrate dehydrogenase inhibitor, #antineoplastic, #G5J396CG5J

Lanoracopan

 

Lanoracopan

CAS 2797066-85-2

MFC27H32N2O4 MW448.6 g/mol

4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid

Benzoic acid, 4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]-

4-{(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid
complement factor B inhibitor, MY 008211A, Factor B-IN-5, Y5UN7AE8SF

Lanoracopan (also known by its developmental code MY008211A or Factor B-IN-5) is an investigational small-molecule drug that acts as a potent complement factor B (CFB) inhibitor. It is designed to target and regulate the alternative pathway of the complement system, which is a crucial part of the body's innate immune defense

Clinical Development & Indications

Originally developed by Shanghai Meiyue Biotech Development Co. Ltd., the drug has transitioned from early discovery into active clinical trials. It is primarily being evaluated for:

1. Paroxysmal Nocturnal Hemoglobinuria (PNH): Lanoracopan (as MY008211A tablets) is currently undergoing Phase 2 and Phase 2/3 clinical trials. These studies assess its long-term safety, tolerability, and efficacy in patients suffering from PNH who experience active hemolysis (the premature destruction of red blood cells).
2. Renal Impairment Studies: Clinical research is also actively evaluating the drug's safety profile and pharmacokinetics in individuals with varying degrees of kidney function.

Current Status

Lanoracopan is recognized under the World Health Organization's proposed International Nonproprietary Names (INN) registry. It is not yet approved for public use or commercial medical prescriptions by global regulatory bodies. Currently, it is primarily available to the scientific community as a reference standard for laboratory research use only

SYN

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023020566&_cid=P21-MQD5YH-25997-1

Example 4: 

[0727]4-((2S,4S)-4-(cyclopropylmethoxy)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (compound 4) 

[0728]

4-((2S,4S)-4-(cyclopropylmethoxy)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid

[0755]The mixture (130 mg) of the above-mentioned tert-butyl 4-(((2S,4S)-4-(cyclopropylmethoxy)-2-(4-(((cyclopropylmethoxy)carbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1H-indole-1-carboxylic acid (tert-butyl ester) and 4-(((2S,4S)-4-(cyclopropylmethoxy)-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1H-indole-1-carboxylic acid (tert-butyl ester) (4c-2) was dissolved in 10 mL of methanol, and solid potassium carbonate (149 mg, 1.08 mmol) was added. The mixture was heated to 85 °C and refluxed for 3 h. The reaction solution was cooled to room temperature and concentrated under reduced pressure to obtain the crude product. The crude product was dissolved in a mixed solvent of 10 mL THF, 5 mL methanol, and 2 mL water. Lithium hydroxide monohydrate (181 mg, 4.3 mmol) was added, and the mixture was stirred at room temperature for 16 h. The reaction system was concentrated under reduced pressure, and the crude product was subjected to Pre-HPLC (instrument and preparative column: Glison GX-281 preparative HPLC system; Sunfire C18 column, 5 μm, inner diameter × length = 30 mm × 150 mm). Preparation method: The crude product was dissolved in methanol and dimethyl sulfoxide, and filtered through a 0.45 μm filter membrane to prepare the sample solution. Mobile phase system: acetonitrile/aqueous solution containing 5 mmol/L ammonium acetate. Gradient elution method: Acetonitrile was used to elute 60% of the solution with a 5% gradient (elution time 15 min), and the solution was lyophilized to obtain 4-((2S,4S)-4-(cyclopropylmethoxy)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (compound 4) (5 mg). 

[0756]

¹H NMR(400MHz,CD ₃OD)δ8.10(d,2H),7.60(d,2H),7.28(d,1H),6.73(s,1H),6.32(s,1H),4.70–4.40(m,1H),4.32–4.14(m,1H),4.09–3.90(m,1H),3.88–3.79(m,1H),3.75(s, 3H),3.42–3.34(m,2H),3.30–3.14(m,2H),2.49(s,3H),2.26–2.10(m,2H),2.06–1.90(m,2H),1.19–1.04(m,1H),0.64–0.50(m,2H),0.31–0.22(m,2H).

[0757]

LCMS m/z＝449.2[M+1] ⁺

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

PAT

• Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicinePublication Number: WO-2023020566-A1Priority Date: 2021-08-18
• Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicinePublication Number: US-2024383917-A1Priority Date: 2021-08-18
• A benzazaaromatic ring derivative and its application in medicinePublication Number: CN-118043314-APriority Date: 2021-08-18
• Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicinePublication Number: EP-4389742-A1Priority Date: 2021-08-18
• Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereofPublication Number: EP-4194451-A1Priority Date: 2020-08-07
• Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereofPublication Number: EP-4282486-A2Priority Date: 2020-08-07
• Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereofPublication Number: US-2023286947-A1Priority Date: 2020-08-07

/////////lanoracopan, anax labs, complement factor B inhibitor, MY 008211A, Factor B-IN-5, Y5UN7AE8SF

#lanoracopan, #anax labs, #complement factor B inhibitor, #MY 008211A, #Factor B-IN-5, #Y5UN7AE8SF

Laporolimus

 

Laporolimus

Rapamycin, 42-cyclohexanecarboxylate

CAS 1504576-27-5

MF C58H89NO14 MW 1024.3 g/mol

[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0^4,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] cyclohexanecarboxylate

(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,3
1,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl
cyclohexanecarboxylate
immunosuppressant, CRC-015, CRC 015, F5041W3RVA, Rapamycin, 42-cyclohexanecarboxylate

Laporolimus is an experimental immunosuppressant compound that acts as an mTOR (mechanistic target of rapamycin) pathway inhibitor. It is chemically classified as a macrolide derivative and is also known by its chemical synonym, rapamycin 42-cyclohexanecarboxylate.

Currently, Laporolimus is designated for research use only and has not been approved for clinical medical applications in humans or animals.

Key Technical Details

• Mechanism of Action: It blocks the mTOR signaling pathway, which is responsible for regulating cell growth, proliferation, and immune cell activation.

Distinguishing Laporolimus from Clinical Alternatives

Because it ends with the suffix -limus, it shares structural and nomenclature similarities with widely used clinical immunosuppressants. However, its legal status and development stage differ significantly:

Drug Name	Clinical Availability	Primary Mechanism	Primary Uses
Laporolimus	None (Research Only)	mTOR Inhibitor	Laboratory research
Sirolimus (Rapamycin)	Approved	mTOR Inhibitor	Transplant rejection, coating coronary stents
Tacrolimus	Approved	Calcineurin Inhibitor	Organ transplant prophylaxis, severe eczema

If you are researching this compound for a laboratory study, you can review its structural data and biochemical properties via the PubChem Laporolimus Compound Page

Laporolimus (CAS 1504576-27-5) is an immunosuppressive agent and mTOR inhibitor structurally derived from rapamycin as a cyclohexanecarboxylate derivative. Its total chemical synthesis is highly complex, typically achieved via semisynthesis starting from natural macrolides produced by Streptomyces fermentation.

Semisynthetic Pathway

Because the core macrocyclic lactone (a 36-membered polyketide ring) is incredibly challenging to build from scratch, researchers and pharmaceutical manufacturers rely on a derivatization approach:

1. Fermentation: The baseline macrolide is produced via large-scale fermentation of Streptomyces hygroscopicus (similar to the base rapamycin process).
2. Purification: The naturally produced macrocyclic core is isolated and purified from the fermentation broth using column chromatography.
3. Esterification: The C-42 hydroxyl group of the macrolide core is selectively protected and subjected to acylation with a cyclohexanecarboxylic acid derivative (or reactive cyclohexanecarbonyl chloride).
4. Deprotection & Purification: The C-42 cyclohexanecarboxylate is then deprotected and purified via preparative chromatography to yield pure laporolimus.

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

PAT

/////////laporolimus, immunosuppressant, CRC-015, CRC 015, F5041W3RVA, Rapamycin, 42-cyclohexanecarboxylate

#laporolimus, #immunosuppressant, #CRC-015, #CRC 015, #F5041W3RVA, #Rapamycin, #42-cyclohexanecarboxylate

Larubrilstat

 

Larubrilstat

CAS 2765226-31-9

MF C21H25N5O2 MW379.5 g/mol

[2-[[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]pyrimidin-5-yl]-(8-oxa-2-azaspiro[4.5]decan-2-yl)methanone

• [2-[[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]pyrimidin-5-yl]-(8-oxa-2-azaspiro[4.5]decan-2-yl)methanone
• Methanone, [2-[[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]-5-pyrimidinyl]-8-oxa-2-azaspiro[4.5]dec-2-yl-

(2-{[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino}pyrimidin-5-yl)(8-oxa-2-azaspiro[4.5]decan-2-
yl)methanone
vascular non-inflammatory molecule-1 (VNN1) inhibitor, AG6K4Y29B4

Larubrilstat is the International Nonproprietary Name (INN) for an experimental, small-molecule vascular non-inflammatory molecule-1 (VNN1) inhibitor. VNN1, also commonly known as Vanin-1 or pantetheinase, is an enzyme involved in tissue response to oxidative stress and inflammation.

Current Status

• Development Context: Larubrilstat is a designated compound linked to therapeutic exploration in inflammatory pathways. Research and patent filings, such as those cataloged by the IUPHAR/BPS Guide to PHARMACOLOGY, track its evaluation alongside similar Vanin-1 inhibitors

SYN

US20240083873,

https://patentscope.wipo.int/search/en/detail.jsf?docId=US425298584&_cid=P20-MQHGA8-93141-1

COMP 2-1 IS PRODUCT

Example 2: Synthesis of Compound 2, Compound 2-1 and Compound 2-2

Step 1

To a solution of compound 2a (500 mg) in ethanol/water (v/v=4:1, 10 mL) mixed solvent was added successively sodium acetate (740 mg) and hydroxylamine hydrochloride (630 mg). The resulting reaction mixture was heated to 94° C. and stirred continuously for 2 hours. The reaction was completed. The reaction mixture was cooled, added with water (50 mL), and then extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product of compound 2b (500 mg).

Step 2

To a solution of compound 2b (320 mg) in acetic acid (6 mL) was added zinc powder (421 mg) in batches. The resulting reaction mixture was heated to 70° C. and stirred continuously for 2 hours. The reaction was completed. The mixture was cooled, filtered and concentrated. The reaction mixture was added with NaOH aqueous solution (10%) to adjust the pH to 9, and then extracted with ethyl acetate (20 mL×4). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product of compound 2c (100 mg).

Step 3

Compound 2 (66 mg) was obtained from compound if (168 mg) and compound 2c (100 mg) according to the method of Example 1.

1H NMR (400 MHz, MeOH-d 4) δ 8.58 (s, 2H), 8.35 (d, J=4.69 Hz, 1H), 7.78-7.70 (m, 1H), 7.27-7.18 (m, 1H), 5.71 (t, J=7.15 Hz, 1H), 3.80-3.59 (m, 6H), 3.54 (d, J=20.77 Hz, 2H), 3.13 (ddd, J=16.55, 9.14, 3.68 Hz, 1H), 3.00 (td, J=16.84, 8.51 Hz, 1H), 2.67 (ddd, J=16.06, 8.24, 3.91 Hz, 1H), 2.14-1.99 (m, 1H), 1.93 (dd, J=16.94, 7.33 Hz, 2H), 1.72-1.51 (m, 4H).

LCMS (ESI), [M+H] +=380.3

Two enantiomers 2-1 (retention time: 8.483 min) and 2-2 (retention time: 13.580 min) were obtained by chiral separation of compound 2.

The chromatographic conditions are as follows:chromatographic column: CHIRALPAK AD-H (5 μm, 4.6×250 mm)flow rate: 0.4 mL/minwavelength: 254 nmcolumn temperature: 35° C.mobile phase: A: n-hexane, B: isopropanol, A:B=1:4run time: 50 min Preparation Method of Compound 2-1

Step 4: Preparation of Compound 2-1

Compound 2-1e (284 g, 1.375 mol), compound 2-1f (350 g, 1.25 mol) and K 2CO 3 (862.5 g, 6.25 mol) were dissolved in isopropanol, and the reaction mixture was heated at reflux overnight. After the reaction was completed, the reaction mixture was cooled to room temperature. The reaction system was distilled under reduced pressure to remove the solvent, added with dichloromethane, stirred, and filtered. The filtrate was dissolved in 2 N HCl, and the pH of the aqueous phase was adjusted to 8 to 9 by adding 1 N NaOH. The mixture was extracted with dichloromethane, dried and concentrated to obtain compound 2-1.

1H NMR (400 MHz, CD 3OD) δ 8.58 (s, 2H), 8.37 (d, J=5.1 Hz, 1H), 7.77 (s, 1H), 7.26 (d, J=2.5 Hz, 1H), 5.72 (t, J=7.7 Hz, 1H), 4.53 (s, 2H), 3.80-3.58 (m, 7H), 3.54 (d, J=18.8 Hz, 2H), 3.15 (ddd, J=16.9, 9.2, 3.7 Hz, 1H), 3.02 (dt, J=16.8, 8.5 Hz, 1H), 2.68 (dq, J=12.8, 4.4 Hz, 1H), 2.14-2.02 (m, 1H), 1.93 (q, J=8.1 Hz, 2H), 1.67 (d, J=5.8 Hz, 2H), 1.59 (d, J=5.7 Hz, 2H).

The absolute stereochemical configuration of compound 2-1 was determined by comparative determination of the above preparation method of the chiral compounds.

PAT

https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=28F257EBC3EA6EE7D447E4442C7CC489.wapp2nA?docId=US458059800&_cid=P20-MQHG5H-85832-1

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

PAT

• Pyrimidine carboxamide compound and application thereofPublication Number: US-2024083873-A1Priority Date: 2020-09-25
• Pyrimidine carboxamide compound and application thereofPublication Number: WO-2022063197-A1Priority Date: 2020-09-25
• Pyrimidine carboxamide compound and application thereofPublication Number: WO-2022063333-A1Priority Date: 2020-09-25

////////larubrilstat, ANAX LABS, vascular non-inflammatory molecule-1 (VNN1) inhibitor, AG6K4Y29B4

#larubrilstat, #ANAX LABS, #vascular non-inflammatory molecule-1 (VNN1) inhibitor, #AG6K4Y29B4

Lasmotinib

 

Lasmotinib

CAS 2127107-15-5

MF C19H19FN4O2S MW386.4 g/mol

3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide

• N-(2-(N-((3S)(3-Piperidyl))carbamoyl)-5-(2-(3-fluorophenyl)ethynyl)(3-thienyl))aminamide
• 2-Thiophenecarboxamide, 3-((aminocarbonyl)amino)-5-(2-(3-fluorophenyl)ethynyl)-N-(3S)-3-piperidinyl-
• 3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide
• 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-(3-fluorophenyl)ethynyl]-N-(3S)-3-piperidinyl-
• 3-(carbamoylamino)-5-(2-(3-fluorophenyl)ethynyl)-N-((3S)-piperidin-3-yl)thiophene-2-carboxamide

3-(carbamoylamino)-5-[(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide
tyrosine kinase inhibitor, antineoplastic, PHI-101, PHI 101, U2UY9TBQ8Z

Lasmotinib (also known by its research code PHI-101) is a next-generation, orally bioavailable targeted cancer therapy. It functions as a dual FLT3 and CHK2 inhibitor. It is primarily being investigated to treat Acute Myeloid Leukemia (AML) and ovarian cancer.

How It Works

• FLT3 Inhibition: It targets FMS-like tyrosine kinase 3 (FLT3), an enzyme that is often mutated in AML. Lasmotinib is designed to attack not just single activating mutations (ITD or TKD), but also difficult-to-treat double and triple-resistant mutations.
• CHK2 Inhibition: It also inhibits Checkpoint Kinase 2 (CHK2), preventing cancer cells from repairing DNA damage. This causes the cancer cells to undergo apoptosis (programmed cell death).

Key Clinical Advantages

• High Efficacy: In relapsed or refractory AML patients who have previously failed other FLT3 inhibitors, lasmotinib has demonstrated high rates of composite complete remission.
• Safety Profile: Preclinical and early-stage trials indicate a promising safety profile with a very low or 0% occurrence rate of cardiotoxicity (heart damage), which is a common hurdle for some other FLT3-targeting drugs.

Current Development & Combinations

• Developer: Discovered by Seoul National University Hospital and being developed by Pharos iBio.
• Synergistic Therapies: Lasmotinib is currently moving into global clinical trials as a powerful combination therapy. Research shows it synergizes strongly with existing treatments like Venetoclax or Azacytidine, as well as with emerging Menin inhibitors (such as bleximenib) to achieve deep tumor growth inhibition

Lasmotinib is an orally bioavailable inhibitor of checkpoint kinase 2 (chk2), with potential antineoplastic and chemopotentiating activities. Upon oral administration, lasmotinib binds to and inhibits the activity of chk2, which may prevent the repair of DNA damage caused by DNA-damaging agents. This may result in tumor cell apoptosis and potentiate the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.

• Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)CTID: NCT04678102Phase: Phase 1Status: Unknown statusDate: 2023-06-26
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AMLCTID: NCT04842370Phase: Phase 1Status: Unknown statusDate: 2021-04-20

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=JP405710409&_cid=P21-MQIVJB-43702-2

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=US465154324&_cid=P21-MQIVJB-43702-2

SYN

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024015484&_cid=P21-MQIVJB-43702-2

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025210599&_cid=P21-MQIVJB-43702-2

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

PAT

• Inhibitors of brutons tyrosine kinasePublication Number: US-2021070748-A1Priority Date: 2015-06-02
• New, substituted quinoline compounds as inhibitors of S-nitrosoglutathion reductasePublication Number: HU-E025653-T2Priority Date: 2010-10-08
• New hybrid oligomers. Their preparation process and pharmaceutical compositions containing themPublication Number: AU-2006256439-A1Priority Date: 2005-03-18
• NEW THIOPHENE COMPOUND SUBSTITUTED IN POSITIONS 2,3,5, USED AS A PROTEIN KINASE INHIBITORPublication Number: BR-112018016729-B1Priority Date: 2016-02-16
• 2, 3, 5-substituted thiophene compounds as protein kinase inhibitorsPublication Number: CN-108884066-BPriority Date: 2016-02-16Grant Date: 2021-08-24
• 2,3,5-substituted thiophene compound as protein kinase inhibitorPublication Number: US-10442796-B2Priority Date: 2016-02-16Grant Date: 2019-10-15
• Novel compound of 2,3,5-substituted thiophene as a protein kinase inhibitorPublication Number: RU-2724957-C2Priority Date: 2016-02-16Grant Date: 2020-06-29
• Novel 2,3,5-substituted thiophene compounds as protein kinase inhibitorsPublication Number: KR-101965326-B1Priority Date: 2016-02-16Grant Date: 2019-04-03
• Novel 2,3,5-substituted thiophene compound as protein kinase inhibitorPublication Number: WO-2017142325-A1Priority Date: 2016-02-16
• Novel 2,3,5-substituted thiophene compound as protein kinase inhibitorPublication Number: US-2019047993-A1Priority Date: 2016-02-16
• Novel 2,3,5-substituted thiophene compounds as protein kinase inhibitorsPublication Number: KR-20180136425-APriority Date: 2016-02-16
• Novel 2,3,5-substituted thiophene compound as protein kinase inhibitorPublication Number: EP-3418275-B1Priority Date: 2016-02-16Grant Date: 2021-03-17
• Novel 2,3,5-substituted thiophene compounds that are protein kinase inhibitorsPublication Number: JP-2019504900-APriority Date: 2016-02-16
• Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapyPublication Number: EP-3804719-A1Priority Date: 2018-05-30
• Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancersPublication Number: EP-3804718-A1Priority Date: 2018-05-30
• Novel 2,3,5-substituted thiophene compound as protein kinase inhibitorPublication Number: EP-3418275-A1Priority Date: 2016-02-16
• New 2,3,5-substituted thiophene compound as a protein kinase inhibitorPublication Number: RU-2018130703-APriority Date: 2016-02-16
• Novel 2,3,5-substituted thiophene compounds as protein kinase inhibitorsPublication Number: KR-20190035671-APriority Date: 2016-02-16
• Radiotherapy-enhancing applications of 2,3,5-substituted thiophene compoundsPublication Number: JP-2021525285-APriority Date: 2018-05-30
• Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapyPublication Number: US-2021205289-A1Priority Date: 2018-05-30
• Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Breast CancerPublication Number: KR-102227117-B1Priority Date: 2018-05-30Grant Date: 2021-03-15
• Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Breast CancerPublication Number: KR-20190136976-APriority Date: 2018-05-30
• Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancersPublication Number: US-2021205290-A1Priority Date: 2018-05-30

////////lasmotinib, anax labs, tyrosine kinase inhibitor, antineoplastic, PHI-101, PHI 101, U2UY9TBQ8Z

#lasmotinib, #anax labs, #tyrosine kinase inhibitor, #antineoplastic, #PHI-101, #PHI 101, #U2UY9TBQ8Z